Filing Flows › Integer Holdings (ITGR) › Q3 2026 › vs Q3 2025
Integer Holdings (ITGR) Q3 2026 vs Q3 2025 (year over year)
Integer Holdings's revenue fell $18.0M (-4%) from $468M in Q3 2025 to $450M in Q3 2026. The biggest changes: Cardio & Vascular −$14.1M (-5%); Other Markets −$10.6M (-50%); Cardiac Rhythm Management & Neuromodulation +$6.7M (+4%). Gross margin 22.6% against 27.0% (-4.4 pts).
Integer Holdings, Q3 2026: revenue $450M (-4% year over year), operating margin 6.3%, net earnings $15.0M, operating cash flow $36.6M. The chart draws each line against Q3 2025, the increases inside each band.
Margins
| Q3 2026 | Q3 2025 | Change | |
|---|---|---|---|
| Gross margin | 22.6% | 27.0% | -4.4 pts |
| Operating margin | 6.3% | 12.1% | -5.8 pts |
| Net margin | 3.3% | 8.5% | -5.2 pts |
| Free cash flow margin | 3.6% | 9.9% | -6.3 pts |
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Cardio & Vascular | $263M | $277M | −$14.1M | -5% |
| Cardiac Rhythm Management & Neuromodulation | $176M | $169M | $6.7M | +4% |
| Other Markets | $10.8M | $21.4M | −$10.6M | -50% |
| Revenue | $450M | $468M | −$18.0M | -4% |
| Gross profit | $102M | $126M | −$24.6M | -19% |
| Cost of revenue | $348M | $342M | $6.6M | +2% |
| Operating profit | $28.2M | $56.4M | −$28.2M | -50% |
| Operating expenses | $73.4M | $69.7M | $3.6M | +5% |
| Pre-tax earnings | $17.5M | $46.0M | −$28.5M | -62% |
| Other expense, net | $10.7M | $10.4M | $250K | +2% |
| Research & development | $13.5M | $10.9M | $2.6M | +24% |
| SG&A | $54.1M | $50.5M | $3.7M | +7% |
| Other operating costs | $5.7M | $8.3M | −$2.6M | -32% |
| Net earnings | $15.0M | $39.7M | −$24.7M | -62% |
| Income tax | $2.5M | $6.3M | −$3.8M | -60% |
| Operating cash sources | $54.6M | $77.6M | −$23.1M | -30% |
| Depreciation & amortization | $34.4M | $33.0M | $1.3M | +4% |
| Share-based compensation | $5.2M | $4.9M | $297K | +6% |
| Working capital & other | $17.9M | $12.1M | $5.9M | +49% |
| Operating cash flow | $36.6M | $65.6M | −$29.0M | -44% |
| Free cash flow (OCF − capex) | $16.1M | $46.3M | −$30.2M | -65% |
| Capital expenditures | $20.5M | $19.3M | $1.2M | +6% |
Questions
How much did Integer Holdings's revenue grow year over year in Q3 2026?
Integer Holdings's revenue fell $18.0M (-4%) from $468M in Q3 2025 to $450M in Q3 2026.
What drove Integer Holdings's revenue change in Q3 2026?
Cardio & Vascular −$14.1M (-5%); Other Markets −$10.6M (-50%); Cardiac Rhythm Management & Neuromodulation +$6.7M (+4%).